THMO - Earnings announcements

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif., Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 15, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2023 and provided a corporate strategic update. "During the first quarter, we continued to make progress in building out our 35,500+ square foot state-of-the-art facility in Sacramento, which is a significant part of our transition into a high performance, integrated contract development and manufacturing organization ("CDMO") in the cell and gene therap

Conference Call to be Held on May 15, 2023 RANCHO CORDOVA, Calif., May 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., March 30, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update. "We are transforming ThermoGenesis from a medical device company to a contract development and manufacturing organization ("CDMO") in the cell gene therapy field," commented Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "Our proprietary cell processing technologies, such as the CAR-TXpress™ platfor

Conference Call to be Held on March 30, 2023 RANCHO CORDOVA, Calif., March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please v

Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif., Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the third quarter ended September 30, 2022, and provide a corporate strategic update on Thursday, November 10, 2022. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https:/

Driven by Sales of the AXP, Total Revenues for the Quarter Rose 38% Compared to Prior Year Conference Call to be Held Today at 12:00 p.m. PT/3:00 p.m. ET RANCHO CORDOVA, Calif., Aug. 11, 2022  /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2022 and provided a corporate strategic update. "Clinical trials for CAR-T and other next-generation cell and gene therapeutics have continued unabated, while the industry continues to grapple with  high manufacturing costs and serious capacity limits created by

Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif., Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022. A conference call and webcast will follow at 12:00 p.m. PT/ 3:00 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://ther

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 19, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2022 and provided a corporate strategic update. First Quarter 2022 Highlights On March 24, 2022, entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (Boyalife Genomics), a China-based contract development and manufacturing organization (CDMO) and an affiliate of ThermoGenesis' Chairman and Chief Executive Officer, C

Conference Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif., May 18, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 and provide a corporate strategic update on Thursday, May 19, 2022, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, pleas

Company Signs License Agreement With Boyalife Genomics and will Form TG Biosynthesis Division to Operate as CDMO for Cell and Cell-Based Gene Therapies Leases 35,475 SF To Be Built-Out as cGMP Compliant Facility in Sacramento Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., March 28, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2021 and provided a corporate strategic update on activities related to the development  of a new CDMO cell therapy manufacturing di

Conference Call to be Held on March 28, 2022 RANCHO CORDOVA, Calif., March 23, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 and provide a corporate strategic update on Monday, March 28, 2022, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the cal

RANCHO CORDOVA, Calif., Jan. 11, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), today announced that the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting") will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST. The meeting, originally scheduled for December 16, 2021, was convened and adjourned without any business being conducted due to lack of the required quorum. The Annual Meeting will be held at the Company's corporate headquarters, located at 2711 Citrus Rd., Rancho Cordova, CA 95742. A conference call and webcast will be available for those who wish to participate. To join in the conference call, please dial 1-844-889-4331 (domestic), 1-412-

RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), announced that the Company's Annual Meeting of Stockholders (the "Annual Meeting") scheduled for Thursday, December 16, 2021 at 9:00 a.m. PST, was convened and adjourned without any business being conducted due to lack of the required quorum. A quorum consists of a majority of the shares entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by proxy, at the convening of the Annual Meeting. The Annual Meeting therefore had no quorum and the meeting was adjourned until 9:00 a.m. PST on Thursday, January 13, 2022 at 2711 Citrus Rd., Rancho Cor

RANCHO CORDOVA, Calif., Nov. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2021 and provided a corporate strategic update. "Personalized treatments are the wave of the future in healthcare. As more regenerative medicine treatments, such as CAR-T cell therapies, receive FDA approval, the demand for the manufacturing of cell therapies is only going to continue to grow," stated Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "At the same time, there is a significant unmet nee

RANCHO CORDOVA, Calif., Nov. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 and provide a corporate strategic update on Friday, November 12, 2021, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/

RANCHO CORDOVA, Calif., Aug. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2021 and provided a corporate strategic update. "Cell and gene therapies are poised to continue to revolutionize many areas of medicine, and ThermoGenesis has been a pioneer in the development and commercialization of automated cell processing technologies that provide more efficient, higher-quality and cost-effective manufacturing solutions to move these therapies through the clinic and ultimately, to patients in

RANCHO CORDOVA, Calif., Aug. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 and provide a corporate strategic update on Thursday, August 12, 2021, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/inve

RANCHO CORDOVA, Calif., May 13, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2021 and provided a corporate strategic update. First Quarter Achievements: On February 3, 2021, the Company announced that it completed the development process for its new PXP®-LAVARE System and submitted a Letter to File with an updated device listing to the U.S. Food and Drug Administration (FDA). The GMP compliant PXP-LAVARE allows for fast, automated, and reliable cell washing. It is an optional cell reformula